NLTX News and Press, Neoleukin Therapeutics Inc. From 06/22/20

- NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of de novo proteins using split molecule technology may increase therapeutic index - - Company t...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

SEATTLE, June 15, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced it will host a virtual Investor R&a...

SEATTLE, June 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced the appointment of Erin Lavelle to ...

SEATTLE, May 27, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced that Jonathan Drachman, M.D., Chief ...

-Preclinical Data on Lead Immunotherapy Candidate NL-201 Including Immunogencity Results in Non-Human Primates- -Novel Conditional Activation Platform Enabled by De Novo Protein Technology- -Preclinical Results Demonstrate Ability of NL-201 to Expand and Enhance CAR‑T Cell Act...

SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...

Neoleukin Therapeutics (NASDAQ: NLTX ): Q1 GAAP EPS of -$0.18 beats by $0.06 . More news on: Neoleukin Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- IND submission for NL-201 anticipated by end of 2020 - - Three abstracts to be presented at AACR-II - SEATTLE, May 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computation...

SEATTLE, April 16, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, announced today that, due to the public health im...